Solid molecular Dx sales send Myriad shares rocketing
This article was originally published in Clinica
Stocks in Myriad Genetics hit a seven-year high after the company shot into profit on the back of a solid performance from its core molecular diagnostics business in the first quarter of fiscal 2009.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.